
  
    
      
        Background_NNP
        The_DT synthesis_NN of_IN the_DT neurotransmitter_NN acetylcholine_NN
        (_( ACh_NNP )_) 1_CD in_IN cholinergic_JJ neurons_NNS is_VBZ dependent_JJ on_IN the_DT
        availability_NN of_IN its_PRP$ precursor_NN ,_, choline_NN ,_, most_JJS of_IN which_WDT is_VBZ
        derived_VBN from_IN the_DT circulation_NN (_( reviewed_VBN in_IN [_NN 1_CD ]_NN )_) and_CC
        enters_VBZ cholinergic_JJ neurons_NNS via_IN a_DT process_NN catalyzed_JJ by_IN a_DT
        specific_JJ transporter_NN [_NN 2_CD 3_CD ]_NN ._. Some_DT of_IN the_DT choline_NN used_VBN for_IN
        ACh_NNP synthesis_NN is_VBZ stored_VBN in_IN membrane_NN phosphatidylcholine_NN
        (_( PC_NN )_) ._. Previous_JJ studies_NNS have_VBP shown_VBN that_IN this_DT choline_NN is_VBZ
        liberated_VBD from_IN PC_NN in_IN a_DT one-step_JJ reaction_NN ,_, thus_RB indicating_VBG
        that_IN it_PRP is_VBZ produced_VBN by_IN a_DT phospholipase_NN D_NNP (_( PLD_NNP ,_, EC_NNP 3_CD ._. 1_CD ._. 4_LS ._. 4_LS )_)
        -_: an_DT enzyme_NN that_IN hydrolyzes_NNS the_DT phospholipid_NN into_IN choline_NN
        and_CC phosphatidic_JJ acid_NN (_( PA_NNP )_) [_NN 4_CD ]_NN ._. However_RB ,_, the_DT molecular_JJ
        identity_NN of_IN this_DT PLD_NNP remains_VBZ to_TO be_VB determined_VBN ._.
        There_EX are_VBP two_CD distinct_JJ PC-specific_NNP mammalian_JJ PLDs_NNP ,_,
        designated_VBN as_IN PLD_NNP 1_CD and_CC PLD_NNP 2_CD and_CC encoded_JJ by_IN separate_JJ genes_NNS [_NN
        5_CD 6_CD ]_NN ._. The_DT two_CD enzymes_NNS share_VBP 50_CD %_NN amino-acid_JJ identity_NN ,_,
        however_RB ,_, regulation_NN of_IN their_PRP$ activity_NN and_CC cellular_JJ
        localization_NN are_VBP different_JJ ._. PLD_NNP 1_CD is_VBZ an_DT extracellular_NN
        signal-activated_JJ phospholipase_NN ;_: its_PRP$ activity_NN rises_VBZ when_WRB
        receptors_NNS for_IN certain_JJ hormones_NNS ,_, growth_NN factors_NNS ,_,
        neurotransmitters_NNS ,_, cytokines_NNS ,_, and_CC other_JJ mediators_NNS are_VBP
        activated_VBN ,_, and_CC upon_IN treatment_NN of_IN cells_NNS with_IN phorbol_NN esters_NNS
        (_( reviewed_VBN in_IN [_NN 7_CD 8_CD ]_NN )_) ._. Studies_NNPS using_VBG recombinant_JJ PLD_NNP 1_CD
        tagged_VBN with_IN green_JJ fluorescent_NN protein_NN or_CC Flu-epitopes_NNP
        indicate_VBP that_IN it_PRP is_VBZ localized_VBN in_IN the_DT endoplasmic_JJ reticulum_NN ,_,
        Golgi_NNP apparatus_NN ,_, late_JJ endosomes_NNS ,_, and_CC plasma_NN membrane_NN (_( [_NN 6_CD
        ]_NN ,_, reviewed_VBN in_IN [_NN 7_CD ]_NN )_) ._. In_IN vitro_NN ,_, basal_NN PLD_NNP 1_CD activity_NN is_VBZ
        usually_RB low_JJ and_CC can_MD be_VB stimulated_VBN by_IN a_DT variety_NN of_IN factors_NNS ,_,
        including_VBG phosphatidylinositol_NN 4_CD ,_, 5_CD -_: bisphosphate_NN (_( PIP_NNP 
        2_LS )_) ,_, protein_NN kinase_NN C_NNP (_( PKC_NNP )_) ,_, and_CC several_JJ
        small_JJ GTPases_NNP ,_, e_SYM ._. g_SYM ._. ADP_NNP ribosylation_NN factors_NNS (_( ARF_NNP )_) and_CC Rho_NNP
        (_( reviewed_VBN in_IN [_NN 7_CD 8_CD ]_NN )_) ._. Regulation_NNP of_IN PLD_NNP 2_CD is_VBZ less_RBR well_RB
        understood_VBN ._. The_DT enzyme_NN exhibits_VBZ a_DT high_JJ constitutive_JJ
        activity_NN in_IN vitro_NN ,_, but_CC it_PRP too_RB can_MD be_VB activated_VBN by_IN ARF_NNP
        (_( reviewed_VBN in_IN [_NN 7_CD ]_NN )_) ,_, and_CC by_IN phorbol_NN esters_NNS ,_, in_IN intact_JJ
        cells_NNS [_NN 6_CD 9_CD ]_NN ._. Several_JJ reports_NNS have_VBP suggested_VBN that_IN PLD_NNP 2_CD is_VBZ
        mainly_RB localized_VBN to_TO the_DT plasma_NN membrane_NN [_NN 6_CD 10_CD ]_NN ,_, possibly_RB
        in_IN lipid_NN rafts_NNS and_CC caveolar_NN membrane_NN microdomains_NNS [_NN 11_CD 12_CD ]_NN
        ._. Most_JJS studies_NNS on_IN the_DT physiological_JJ functions_NNS of_IN PLDs_NNP have_VBP
        focused_VBN on_IN the_DT product_NN PA_NNP ,_, a_DT second_JJ messenger_NN involved_VBN in_IN
        mitosis_NNS ,_, cellular_JJ morphological_JJ changes_NNS and_CC vesicular_NN
        trafficking_NN (_( reviewed_VBN in_IN [_NN 7_CD 13_CD ]_NN )_) ._. However_RB ,_, the_DT
        downstream_JJ events_NNS that_WDT occur_VBP as_IN a_DT consequence_NN of_IN
        PLD-generated_NNP PA_NNP production_NN ,_, and_CC the_DT identity_NN of_IN target_NN
        proteins_NNS that_WDT are_VBP directly_RB regulated_VBN by_IN PA_NNP remains_VBZ to_TO be_VB
        determined_VBN ._. PA_NNP can_MD be_VB further_RBR metabolized_VBN to_TO diacylglycerol_NN
        (_( DAG_NNP )_) and_CC lysophosphatidic_JJ acid_NN by_IN PA_NNP phosphohydrolase_NN and_CC
        phospholipase_NN A_DT 
        2_CD ,_, respectively_RB ._. DAG_NNP is_VBZ an_DT activator_NN of_IN
        certain_JJ isozymes_NNS of_IN PKC_NNP and_CC lysophosphatidic_JJ acid_NN acts_NNS as_IN
        an_DT intercellular_NN messenger_NN for_IN many_JJ cell_NN types_NNS ._.
        The_DT second_JJ product_NN of_IN PLD-catalyzed_NNP PC_NNP hydrolysis_NNS ,_,
        choline_NN ,_, is_VBZ used_VBN by_IN all_DT cells_NNS as_IN a_DT precursor_NN of_IN PC_NN ,_, and_CC
        uniquely_RB by_IN cholinergic_JJ neurons_NNS as_IN precursor_NN of_IN ACh_NNP ._.
        Previous_JJ studies_NNS have_VBP shown_VBN that_DT choline_NN derived_VBN from_IN PC_NN is_VBZ
        indeed_RB used_VBN for_IN ACh_NNP synthesis_NN [_NN 4_CD 14_CD 15_CD 16_CD ]_NN and_CC that_IN this_DT
        choline_NN is_VBZ generated_VBN by_IN a_DT PLD_NNP [_NN 4_CD 14_CD ]_NN ._. This_DT pathway_NN may_MD
        become_VB particularly_RB important_JJ when_WRB extracellular_NN
        circulating_VBG choline_NN concentrations_NNS are_VBP low_JJ (_( e_SYM ._. g_SYM ._. during_IN
        dietary_JJ choline_NN deficiency_NN )_) or_CC when_WRB ACh_NNP synthesis_NN and_CC
        release_NN are_VBP accelerated_VBN by_IN high_JJ neuronal_NN activity_NN ,_, thus_RB
        generating_VBG a_DT high_JJ demand_NN for_IN choline_NN [_NN 16_CD ]_NN ._.
        In_IN the_DT present_JJ study_NN ,_, we_PRP used_VBD a_DT cholinergic_JJ cell_NN line_NN ,_,
        SN_NNP 56_CD [_NN 17_CD ]_NN ,_, which_WDT is_VBZ derived_VBN from_IN the_DT fusion_NN of_IN septal_NN
        neurons_NNS of_IN postnatal_NN day_NN 21_CD mice_NNS with_IN N_NNP 18_CD TG_NNP 2_CD murine_NN
        neuroblastoma_NN cells_NNS ,_, as_IN a_DT model_NN for_IN cholinergic_JJ neurons_NNS ,_, in_IN
        order_NN to_TO determine_VB the_DT possible_JJ role_NN of_IN PLD_NNP 1_CD and_CC PLD_NNP 2_CD in_IN
        generating_NN choline_NN for_IN ACh_NNP synthesis_NN ._. We_PRP found_VBD that_IN the_DT
        cells_NNS express_VBP exclusively_RB PLD_NNP 2_CD and_CC that_IN downregulating_VBG PLD_NNP 2_CD
        expression_NN reduces_VBZ ACh_NNP synthesis_NN ,_, while_IN overexpressing_VBG
        and_CC /_NN or_CC stimulating_VBG PLD_NNP 2_CD activity_NN increases_VBZ the_DT synthesis_NN of_IN
        the_DT neurotransmitter_NN ,_, indicating_VBG that_IN PLD_NNP 2_CD -_: catalyzed_JJ
        hydrolysis_NNS of_IN PC_NN generates_VBZ choline_NN for_IN ACh_NNP synthesis_NN in_IN
        cholinergic_JJ cells_NNS ._.
      
      
        Results_NNS
        PLD_NNP 2_CD mRNA_NN was_VBD present_JJ in_IN SN_NNP 56_CD cells_NNS (_( Fig_NNP ._. 1_LS A_DT )_) while_IN PLD_NNP 1_CD
        message_NN was_VBD undetectable_JJ either_CC by_IN Northern_NNP blot_NN (_( Fig_NNP ._. 1_LS A_DT )_)
        or_CC RT-PCR_NNP (_( data_NNS not_RB shown_VBN )_) ._. Consistent_NNP with_IN these_DT results_NNS
        an_DT approximately_RB 90_CD kDa_NN PLD_NNP 2_CD protein_NN was_VBD found_VBN in_IN SN_NNP 56_CD
        cells_NNS by_IN Western_JJ blot_NN ;_: however_RB ,_, no_DT PLD_NNP 1_CD protein_NN could_MD be_VB
        detected_VBN (_( Fig_NNP ._. 1_LS B_NNP )_) ._. Positive_JJ controls_NNS for_IN these_DT studies_NNS
        showed_VBD that_IN our_PRP$ PLD_NNP 1_CD probe_NN and_CC antibody_NN were_VBD robust_JJ in_IN
        detecting_VBG this_DT PLD_NNP isoform_NN in_IN rat_NN brain_NN (_( Fig_NNP ._. 1_LS )_) ._. These_DT
        data_NNS show_VBP that_IN SN_NNP 56_CD cells_NNS express_VBP exclusively_RB PLD_NNP 2_CD and_CC thus_RB
        experimental_JJ manipulations_NNS of_IN the_DT activity_NN of_IN this_DT PLD_NNP
        isoform_NN were_VBD subsequently_RB employed_VBN to_TO determine_VB if_IN this_DT
        enzyme_NN is_VBZ capable_JJ of_IN producing_VBG choline_NN for_IN ACh_NNP synthesis_NN in_IN
        cholinergic_JJ cells_NNS ._. In_IN order_NN to_TO reduce_VB PLD_NNP 2_CD activity_NN in_IN SN_NNP 56_CD
        cells_NNS ,_, we_PRP sought_VBD to_TO inhibit_VB its_PRP$ expression_NN ._. The_DT cells_NNS were_VBD
        treated_VBN with_IN a_DT 25_CD -_: mer_NN antisense_NN oligonucleotide_NN at_IN
        different_JJ concentrations_NNS and_CC PLD_NNP 2_CD mRNA_NN levels_NNS were_VBD
        measured_VBN ._. Northern_JJ blot_NN showed_VBD that_IN PLD_NNP 2_CD mRNA_NN expression_NN
        was_VBD reduced_VBN by_IN the_DT antisense_NN oligonucleotide_NN in_IN a_DT
        concentration-dependent_JJ manner_NN (_( Fig_NNP ._. 2_LS A_DT )_) ,_, and_CC that_IN ,_, at_IN the_DT
        maximally-effective_JJ concentration_NN of_IN the_DT oligo_NN (_( 200_CD nM_NN )_) ,_,
        this_DT inhibition_NN reached_VBD 34_CD %_NN (_( Fig_NNP ._. 2_LS B_NNP ,_, C_NNP )_) ._. In_IN contrast_NN ,_, the_DT
        control_NN oligomer_NN was_VBD inactive_JJ (_( Fig_NNP ._. 2_LS B_NNP ,_, C_NNP )_) ._. Consistent_NNP with_IN
        these_DT findings_NNS ._. Western_JJ blot_NN showed_VBD that_IN the_DT antisense_NN
        oligomer_NN decreased_VBD the_DT PLD_NNP 2_CD protein_NN level_NN by_IN about_IN 28_CD %_NN ,_,
        whereas_IN the_DT control_NN oligomer_NN had_VBD no_DT significant_JJ effect_NN on_IN
        PLD_NNP 2_CD protein_NN expression_NN (_( Fig_NNP ._. 2_LS D_NNP ,_, E_NNP )_) ._. Given_VBN the_DT fact_NN that_IN
        the_DT transfection_NN efficiency_NN obtained_VBN in_IN these_DT experiments_NNS
        was_VBD approximately_RB 30_CD %_NN (_( as_IN determined_VBN with_IN fluorescent_NN
        dye-labeled_JJ oligonucleotides_NNS ;_: data_NNS not_RB shown_VBN )_) ,_, the_DT results_NNS
        indicate_VBP that_IN ,_, in_IN cells_NNS that_WDT had_VBD taken_VBN up_RP the_DT antisense_NN
        oligomer_NN ,_, the_DT inhibition_NN of_IN PLD_NNP 2_CD expression_NN was_VBD
        complete_JJ ._.
        Treatment_NNP of_IN a_DT variety_NN of_IN cell_NN types_NNS with_IN phorbol_NN esters_NNS
        activates_NNS PLD_NNP 2_CD [_NN 6_CD 12_CD 18_CD 19_CD ]_NN ._. Thus_RB we_PRP hypothesized_VBN that_DT
        activation_NN of_IN PLD_NNP with_IN PMA_NNP in_IN SN_NNP 56_CD cells_NNS would_MD elevate_NN
        intracellular_NN concentrations_NNS of_IN its_PRP$ product_NN ,_, choline_NN ,_, and_CC
        result_NN in_IN increased_VBN ACh_NNP production_NN ._. We_PRP tested_VBD the_DT effects_NNS
        of_IN PMA_NNP on_IN PLD_NNP activity_NN and_CC ACh_NNP content_NN in_IN SN_NNP 56_CD cells_NNS
        incubated_JJ in_IN a_DT choline-free_JJ medium_NN ._. Under_IN these_DT conditions_NNS
        the_DT choline_NN precursor_NN used_VBN for_IN the_DT synthesis_NN of_IN ACh_NNP is_VBZ
        derived_VBN entirely_RB from_IN the_DT intracellular_NN pool_NN ,_, which_WDT
        includes_VBZ the_DT choline_NN in_IN PC_NN [_NN 4_CD 15_CD ]_NN ._. Consistent_NNP with_IN
        previous_JJ studies_NNS ,_, treatment_NN of_IN the_DT cells_NNS with_IN PMA_NNP activated_VBN
        PLD_NNP (_( Fig_NNP ._. 3_LS A_DT )_) ._. The_DT maximal_NN effects_NNS of_IN PMA_NNP (_( 3_CD ._. 3_LS fold_VB
        increase_NN in_IN the_DT amount_NN of_IN its_PRP$ product_NN [_NN
        3_CD H_NNP ]_NN phosphatidylpropanol_NN relative_JJ to_TO controls_NNS )_) was_VBD observed_VBN
        after_IN 45_CD minutes_NNS (_( data_NNS not_RB shown_VBN )_) ,_, a_DT time_NN period_NN employed_VBN
        in_IN subsequent_JJ studies_NNS ._. Free_JJ choline_NN accumulation_NN was_VBD also_RB
        significantly_RB increased_VBN by_IN PMA_NNP ._. The_DT magnitude_NN of_IN this_DT
        effect_NN tended_VBD to_TO be_VB small_JJ (_( approximately_RB 15_CD %_NN )_) ,_, presumably_RB
        because_IN free_JJ choline_NN is_VBZ a_DT rapidly_RB turning_VBG over_IN metabolic_JJ
        intermediate_JJ that_WDT does_VBZ not_RB accumulate_VBP in_IN cells_NNS (_( Fig_NNP ._. 3_LS B_NNP )_) ._.
        Moreover_RB ,_, PMA_NNP stimulated_VBN ACh_NNP accumulation_NN by_IN 26_CD %_NN (_( Fig_NNP ._. 3_LS C_NNP )_) ,_,
        in_IN the_DT cells_NNS ._. The_DT fact_NN that_IN PMA_NNP increased_VBD both_DT PLD_NNP activity_NN
        and_CC ACh_NNP content_NN provided_VBD the_DT initial_JJ evidence_NN for_IN a_DT
        relationship_NN between_IN the_DT endogenous_JJ PLD_NNP activity_NN (_( i_NNP ._. e_SYM ._.
        PLD_NNP 2_LS )_) and_CC ACh_NNP production_NN ._. In_IN control_NN studies_NNS performed_VBN in_IN
        the_DT presence_NN of_IN choline_NN (_( 15_CD μM_NN )_) in_IN the_DT medium_JJ PMA_NNP had_VBD no_DT
        effect_NN on_IN ACh_NNP levels_NNS (_( data_NNS not_RB shown_VBN )_) ,_, indicating_VBG that_IN it_PRP
        did_VBD not_RB stimulate_VB the_DT process_NN of_IN ACh_NNP synthesis_NN but_CC only_RB the_DT
        supply_NN of_IN choline_NN ._.
        Next_JJ the_DT effect_NN of_IN downregulation_NN of_IN PLD_NNP 2_CD activity_NN on_IN
        ACh_NNP levels_NNS was_VBD studied_VBN in_IN cells_NNS transfected_JJ with_IN either_DT
        control_NN or_CC antisense_NN oligomer_NN and_CC treated_VBN with_IN PMA_NNP ._. In_IN the_DT
        absence_NN of_IN PMA_NNP ,_, the_DT antisense_NN oligomer_NN decreased_VBD PLD_NNP 2_CD
        activity_NN by_IN 19_CD %_NN ._. Although_IN small_JJ ,_, this_DT change_NN was_VBD
        statistically_RB significant_JJ (_( p_NN <_NN 0_CD ._. 05_CD )_) ._. In_IN the_DT presence_NN of_IN
        PMA_NNP ,_, antisense_NN oligomer_NN decreased_VBD PLD_NNP 2_CD activity_NN by_IN 27_CD %_NN
        (_( Fig_NNP ._. 3_LS A_DT )_) ._. Concomitantly_NNP the_DT cellular_JJ choline_NN content_NN was_VBD
        decreased_VBN by_IN 30_CD %_NN both_DT in_IN the_DT presence_NN and_CC absence_NN of_IN PMA_NNP by_IN
        the_DT antisense_NN oligomer_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._. Moreover_RB ,_, the_DT antisense_NN
        oligomer_NN decreased_VBD the_DT cellular_JJ ACh_NNP content_NN by_IN
        approximately_RB 30_CD %_NN compared_VBN to_TO control_VB oligomer_NN treated_VBD
        cells_NNS both_DT in_IN the_DT presence_NN and_CC absence_NN of_IN PMA_NNP (_( Fig_NNP ._. 3_LS C_NNP )_) ._.
        These_DT results_NNS indicate_VBP that_DT downregulation_NN of_IN PLD_NNP 2_CD activity_NN
        by_IN antisense_NN oligomers_NNS in_IN SN_NNP 56_CD cells_NNS decreases_NNS not_RB only_RB the_DT
        endogenous_JJ PLD_NNP 2_CD activity_NN but_CC also_RB the_DT intracellular_NN choline_NN
        and_CC ACh_NNP content_NN ._. These_DT results_NNS are_VBP consistent_JJ with_IN the_DT
        hypothesis_NNS that_IN PLD_NNP 2_CD can_MD generate_VB choline_NN for_IN ACh_NNP synthesis_NN
        in_IN SN_NNP 56_CD cells_NNS ._.
        To_TO further_VB confirm_VB this_DT hypothesis_NNS ,_, we_PRP transiently_RB
        transfected_JJ the_DT cells_NNS with_IN a_DT mouse_NN PLD_NNP 2_CD expression_NN plasmid_NN ._.
        Overexpression_NNP of_IN PLD_NNP 2_CD for_IN 48_CD hours_NNS in_IN the_DT cells_NNS caused_VBD a_DT
        74_CD %_NN increase_NN of_IN basal_NN PLD_NNP 2_CD activity_NN and_CC this_DT activity_NN was_VBD
        further_RBR increased_VBN by_IN PMA_NNP by_IN 3_CD ._. 2_CD -_: fold_VB (_( Fig_NNP ._. 4_LS A_DT )_) ._. To_TO examine_VB
        the_DT ACh_NNP synthesis_NN and_CC choline_NN turnover_NN in_IN these_DT PLD_NNP 2_CD
        transfectants_NNS ,_, the_DT cells_NNS and_CC the_DT media_NNS were_VBD collected_VBN and_CC
        ACh_NNP and_CC choline_NN content_NN were_VBD measured_VBN ._. In_IN the_DT absence_NN of_IN
        PMA_NNP ,_, overexpression_NN of_IN PLD_NNP 2_CD alone_RB increased_VBN intracellular_NN
        ACh_NNP levels_NNS by_IN 26_CD %_NN and_CC choline_NN concentrations_NNS in_IN the_DT medium_NN
        by_IN 57_CD %_NN ._. In_IN the_DT presence_NN of_IN PMA_NNP ,_, intracellular_NN ACh_NNP levels_NNS
        and_CC choline_NN concentration_NN in_IN the_DT medium_NN rose_VBD further_RB in_IN the_DT
        PLD_NNP 2_CD transfectants_NNS reaching_VBG values_NNS more_JJR than_IN two-fold_JJ
        higher_JJR than_IN those_DT in_IN the_DT control_NN cells_NNS (_( Fig_NNP ._. 4_LS B_NNP ,_, C_NNP )_) ._.
        Together_RB with_IN the_DT data_NNS presented_VBN above_IN ,_, these_DT results_NNS show_VBP
        that_IN up-regulation_JJ of_IN PLD_NNP 2_CD activity_NN by_IN overexpression_NN
        and_CC /_NN or_CC stimulation_NN with_IN PMA_NNP increases_NNS intracellular_NN ACh_NNP
        levels_NNS ._.
        A_DT recent_JJ immunohistochemical_JJ study_NN of_IN PLD_NNP 1_CD expression_NN in_IN
        rat_NN brain_NN showed_VBD that_IN this_DT PLD_NNP isoform_NN was_VBD expressed_VBN in_IN
        neurons_NNS in_IN medial_NN septum_NN ,_, cranial_NN motor_NN nuclei_NN and_CC ventral_NN
        spinal_JJ cord_NN [_NN 20_CD ]_NN ,_, all_DT areas_NNS of_IN the_DT central_JJ nervous_JJ
        system_NN enriched_JJ with_IN cholinergic_JJ neurons_NNS ._. These_DT data_NNS raised_VBD
        the_DT possibility_NN that_IN certain_JJ populations_NNS of_IN cholinergic_JJ
        neurons_NNS may_MD express_VB PLD_NNP 1_CD in_IN addition_NN to_TO ,_, or_CC instead_RB of_RB ,_,
        PLD_NNP 2_CD ._. Therefore_RB we_PRP transfected_JJ SN_NNP 56_CD cells_NNS with_IN PLD_NNP 1_CD
        expression_NN construct_VB ,_, in_IN order_NN to_TO determine_VB if_IN choline_NN
        generated_VBN by_IN this_DT enzyme_NN could_MD be_VB used_VBN as_IN ACh_NNP precursor_NN ._.
        Transfection_NNP of_IN PLD_NNP 1_CD into_IN SN_NNP 56_CD cells_NNS resulted_VBD in_IN increased_VBN
        PLD_NNP activity_NN and_CC ACh_NNP synthesis_NN in_IN a_DT fashion_NN similar_JJ to_TO that_DT
        observed_VBD in_IN PLD_NNP 2_CD transfectants_NNS (_( Fig_NNP ._. 5_LS )_) indicating_VBG that_DT
        choline_NN generated_VBN by_IN PLD_NNP 1_CD was_VBD converted_VBN to_TO ACh_NNP ._.
      
      
        Discussion_NNP
        In_IN the_DT present_JJ study_NN ,_, we_PRP sought_VBD to_TO establish_VB which_WDT PLD_NNP
        isoform_NN is_VBZ the_DT endogenous_JJ enzyme_NN that_WDT generates_VBZ the_DT choline_NN
        precursor_NN for_IN ACh_NNP synthesis_NN in_IN cholinergic_JJ neurons_NNS using_VBG ,_,
        as_IN a_DT model_NN ,_, the_DT SN_NNP 56_CD basal_NN forebrain_NN cell_NN line_NN ._. We_PRP found_VBD
        that_IN these_DT cells_NNS expressed_VBD exclusively_RB PLD_NNP 2_CD ,_, a_DT property_NN
        that_IN facilitated_JJ subsequent_JJ experiments_NNS ._. First_LS ,_, antisense_NN
        oligonucleotides_NNS were_VBD used_VBN to_TO down-regulate_JJ endogenous_JJ PLD_NNP 2_CD
        activity_NN ._. Although_IN only_RB 30_CD %_NN of_IN the_DT cells_NNS took_VBD up_RP the_DT
        oligonucleotides_NNS ,_, PLD_NNP 2_CD mRNA_NN ,_, protein_NN expression_NN ,_, and_CC
        activity_NN were_VBD reduced_VBN proportionally_RB to_TO the_DT transfection_NN
        efficiency_NN of_IN the_DT antisense_NN oligomer_NN ,_, demonstrating_VBG high_JJ
        efficacy_NN of_IN this_DT technique_NN in_IN the_DT transfected_JJ cells_NNS ._.
        Significantly_RB ,_, intracellular_NN choline_NN and_CC ACh_NNP content_NN were_VBD
        similarly_RB decreased_VBN by_IN the_DT antisense_NN oligonucleotides_NNS ,_,
        indicating_VBG that_IN PLD_NNP 2_CD -_: catalyzed_JJ hydrolysis_NNS of_IN PC_NN provides_VBZ
        choline_NN for_IN ACh_NNP synthesis_NN ._. Next_JJ ,_, PLD_NNP 2_CD activity_NN was_VBD
        up-regulated_JJ by_IN either_DT overexpressing_VBG a_DT mouse_NN PLD_NNP 2_CD protein_NN
        and_CC /_NN or_CC by_IN stimulation_NN with_IN PMA_NNP ._. Both_DT PLD_NNP 2_CD overexpression_NN
        and_CC stimulation_NN with_IN PMA_NNP increased_VBD PLD_NNP activity_NN ,_, choline_NN
        production_NN ,_, and_CC ACh_NNP accumulation_NN ._. Moreover_RB ,_, PLD_NNP 2_CD
        transfection_NN and_CC PMA_NNP treatment_NN had_VBD a_DT synergistic_JJ effect_NN on_IN
        PLD_NNP activity_NN and_CC ACh_NNP levels_NNS ._.
        Our_PRP$ observation_NN that_IN PLD_NNP 2_CD but_CC not_RB PLD_NNP 1_CD was_VBD present_JJ in_IN
        SN_NNP 56_CD cells_NNS raised_VBD the_DT possibility_NN that_IN the_DT former_NN might_MD be_VB
        preferentially_RB expressed_VBN in_IN cholinergic_JJ neurons_NNS ._. The_DT data_NNS
        are_VBP consistent_JJ with_IN the_DT report_NN that_IN a_DT variant_NN of_IN PC_NN 12_CD cells_NNS
        also_RB express_VBP exclusively_RB PLD_NNP 2_CD [_NN 18_CD ]_NN and_CC this_DT expression_NN is_VBZ
        stimulated_VBN by_IN nerve_NN growth_NN factor_NN [_NN 18_CD ]_NN ,_, a_DT treatment_NN
        known_VBN to_TO upregulate_NN the_DT cholinergic_JJ phenotype_NN of_IN PC_NN 12_CD cells_NNS
        [_NN 21_CD 22_CD ]_NN ._. PLD_NNP 2_CD mRNA_NN is_VBZ abundant_JJ in_IN many_JJ regions_NNS of_IN the_DT
        adult_NN rodent_NN central_JJ nervous_JJ system_NN [_NN 6_CD 23_CD ]_NN ,_, including_VBG
        cerebellum_NN ,_, frontal_JJ cortex_NN ,_, hippocampus_JJ ,_, hypothalamus_JJ ,_,
        midbrain_NN ,_, brainstem_NN ,_, striatum_NN ,_, and_CC spinal_JJ cord_NN [_NN 24_CD ]_NN ._. The_DT
        latter_JJ three_CD regions_NNS are_VBP enriched_JJ with_IN cell_NN bodies_NNS of_IN
        cholinergic_JJ neurons_NNS ._. PLD_NNP 1_CD is_VBZ also_RB highly_RB expressed_VBD in_IN brain_NN
        tissue_NN [_NN 6_CD 23_CD 25_CD ]_NN ,_, notably_RB in_IN neurons_NNS in_IN medial_NN septum_NN ,_,
        cranial_NN motor_NN nuclei_NN and_CC ventral_NN spinal_JJ cord_NN [_NN 20_CD ]_NN ,_, all_DT
        of_IN which_WDT are_VBP likely_JJ cholinergic_JJ ._. However_RB ,_, no_DT data_NNS are_VBP
        currently_RB available_JJ on_IN the_DT possible_JJ coexpression_NN of_IN PLD_NNP 1_CD
        and_CC /_NN or_CC PLD_NNP 2_CD and_CC cholinergic_JJ markers_NNS (_( e_SYM ._. g_SYM ._. choline_NN
        acetyltransferase_NN )_) in_IN vivo_NN ._. Transfection_NNP of_IN PLD_NNP 1_CD into_IN SN_NNP 56_CD
        cells_NNS resulted_VBD in_IN increased_VBN PLD_NNP activity_NN and_CC ACh_NNP production_NN
        suggesting_VBG that_IN PLD_NNP 1_CD ,_, like_IN PLD_NNP 2_CD ,_, could_MD potentially_RB be_VB used_VBN
        to_TO supply_VB choline_NN for_IN ACh_NNP synthesis_NN ._. Thus_RB ,_, while_IN the_DT
        catalytic_JJ activities_NNS of_IN both_DT PLD_NNP 1_CD and_CC PLD_NNP 2_CD appear_VB to_TO be_VB
        equivalent_NN in_IN generating_NN choline_NN for_IN ACh_NNP synthesis_NN in_IN
        transfected_JJ cells_NNS ,_, it_PRP is_VBZ possible_JJ that_IN the_DT modes_NNS of_IN
        regulation_NN of_IN their_PRP$ activity_NN might_MD specify_VB which_WDT one_CD is_VBZ
        expressed_VBN in_IN a_DT particular_JJ population_NN of_IN cholinergic_JJ neurons_NNS
        in_IN vivo_NN ._. It_PRP will_MD be_VB important_JJ to_TO determine_VB the_DT mechanisms_NNS
        that_WDT control_NN the_DT expression_NN of_IN the_DT two_CD PLD_NNP isoforms_NNS and_CC
        their_PRP$ possible_JJ relationships_NNS with_IN the_DT mechanisms_NNS that_WDT
        regulate_VB the_DT cholinergic_JJ phenotype_NN ._.
        Stimulation_NNP of_IN PLD_NNP activity_NN by_IN PMA_NNP and_CC the_DT resulting_VBG
        increase_NN of_IN ACh_NNP synthesis_NN from_IN PLD-generated_NNP choline_NN
        indicates_VBZ that_IN this_DT pathway_NN is_VBZ regulated_VBN by_IN PMA-responsive_NNP
        PKC_NNP isozymes_NNS ._. In_IN vivo_NN ,_, this_DT form_NN of_IN regulation_NN of_IN ACh_NNP
        synthesis_NN would_MD be_VB controlled_VBN by_IN neurotransmitters_NNS released_VBN
        by_IN neurons_NNS that_WDT innervate_NN particular_JJ cholinergic_JJ cells_NNS ._.
        There_EX are_VBP multiple_JJ neurotransmitters_NNS whose_WP$ receptors_NNS are_VBP
        coupled_VBN to_TO PKC-dependent_NNP activation_NN of_IN PLD_NNP [_NN 7_CD ]_NN ,_, and_CC thus_RB
        this_DT mode_NN of_IN regulating_VBG the_DT availability_NN of_IN choline_NN for_IN ACh_NNP
        synthesis_NN is_VBZ likely_JJ to_TO be_VB widespread_JJ ._. Significantly_RB ,_, among_IN
        the_DT five_CD subtypes_NNS of_IN muscarinic_JJ ACh_NNP receptors_NNS (_( MAChRs_NNP )_) ,_, Ml_NNP
        and_CC M_NNP 3_CD receptors_NNS have_VBP been_VBN shown_VBN to_TO efficiently_RB activate_VBP
        PLD_NNP (_( and_CC PKC_NNP )_) in_IN various_JJ cell_NN types_NNS [_NN 26_CD 27_CD 28_CD 29_CD 30_CD ]_NN ,_,
        whereas_IN activation_NN of_IN PLD_NNP by_IN M_NNP 2_CD and_CC M_NNP 4_CD receptors_NNS is_VBZ less_RBR
        robust_JJ [_NN 26_CD ]_NN ._. These_DT observations_NNS suggest_VBP that_IN in_IN a_DT
        cholinergic_JJ synapse_NN ,_, ACh_NNP released_VBD into_IN the_DT synaptic_JJ cleft_NN
        might_MD stimulate_VB PLD_NNP activity_NN leading_VBG to_TO a_DT release_NN of_IN
        choline_NN that_WDT could_MD be_VB used_VBN for_IN ACh_NNP synthesis_NN ._. Since_IN these_DT
        MAChRs_NNP may_MD be_VB present_JJ on_IN the_DT pre-_NN and_CC postsynaptic_JJ neurons_NNS
        [_NN 31_CD ]_NN ,_, this_DT choline_NN may_MD be_VB derived_VBN from_IN PC_NN residing_VBG in_IN
        the_DT membranes_NNS of_IN either_RB ._. However_RB ,_, while_IN the_DT
        presynaptically-derived_JJ choline_NN released_VBN into_IN the_DT cytoplasm_NN
        can_MD be_VB converted_VBN directly_RB to_TO ACh_NNP ,_, the_DT choline_NN released_VBN by_IN
        the_DT postsynaptic_JJ cell_NN must_MD be_VB initially_RB taken_VBN up_RP by_IN the_DT
        cholinergic_JJ nerve_NN terminals_NNS ._. Our_PRP$ previous_JJ results_NNS in_IN
        cholinergic_JJ human_JJ neuroblastoma_NN LA-N-_NNP 2_CD cells_NNS indicated_VBD that_IN
        the_DT choline_NN moiety_NN from_IN PC_NN breakdown_NN was_VBD released_VBN directly_RB
        into_IN the_DT cytoplasm_NN [_NN 4_CD ]_NN and_CC a_DT kinetic_JJ study_NN using_VBG [_NN
        3_CD H_NNP ]_NN choline_NN in_IN BHK_NNP cells_NNS also_RB showed_VBD that_DT choline_NN was_VBD
        initially_RB released_VBN inside_IN the_DT cells_NNS by_IN PMA-activated_NNP PLD_NNP
        and_CC then_RB rapidly_RB appeared_VBD in_IN the_DT medium_NN [_NN 32_CD ]_NN ._. Consistent_NNP
        with_IN the_DT latter_JJ study_NN ,_, we_PRP also_RB observed_VBD a_DT rise_NN in_IN the_DT
        medium_NN choline_NN levels_NNS in_IN SN_NNP 56_CD cells_NNS transfected_JJ with_IN either_DT
        PLD_NNP 1_CD or_CC PLD_NNP 2_CD and_CC treated_VBN with_IN PMA_NNP ._.
        Although_IN it_PRP is_VBZ clear_JJ that_IN the_DT PLD-generated_NNP choline_NN is_VBZ
        efficiently_RB utilized_JJ by_IN cholinergic_JJ cells_NNS (_( LA-N-_NNP 2_CD and_CC SN_NNP 56_CD )_)
        as_IN a_DT precursor_NN of_IN ACh_NNP ,_, the_DT quantitative_JJ significance_NN of_IN
        this_DT pathway_NN and_CC mechanisms_NNS that_WDT regulate_VB it_PRP remain_VB to_TO be_VB
        fully_RB determined_VBN ._. Studies_NNS on_IN a_DT variety_NN of_IN preparations_NNS
        indicate_VBP that_IN most_JJS of_IN the_DT choline_NN used_VBN for_IN ACh_NNP synthesis_NN is_VBZ
        derived_VBN from_IN the_DT extracellular_NN space_NN (_( reviewed_VBN in_IN [_NN 1_CD ]_NN )_)
        and_CC therefore_RB the_DT PLD_NNP pathway_NN has_VBZ to_TO be_VB considered_VBN as_IN an_DT
        accessory_JJ process_NN ._. Interestingly_RB ,_, PLD_NNP activity_NN is_VBZ
        upregulated_JJ in_IN the_DT hippocampus_JJ of_IN rats_NNS whose_WP$ mothers_NNS
        consumed_VBD a_DT choline-supplemented_JJ diet_NN during_IN pregnancy_NN [_NN 33_CD
        ]_NN ._. Given_VBN that_DT prenatal_NN choline_NN supplementation_NN improves_VBZ
        memory_NN and_CC attention_NN [_NN 34_CD ]_NN ,_, two_CD cognitive_JJ functions_NNS that_WDT
        require_VBP the_DT hippocampal_NN cholinergic_JJ system_NN ,_, it_PRP is_VBZ possible_JJ
        that_IN the_DT upregulated_JJ PLD_NNP pathway_NN underlies_NNS ,_, at_IN least_JJS in_IN
        part_NN ,_, the_DT cognitive_JJ enhancement_NN observed_VBD in_IN the_DT prenatally_RB
        choline-supplemented_JJ animals_NNS ._.
        Abnormalities_NNP in_IN the_DT PLD-mediated_NNP release_NN of_IN choline_NN
        would_MD be_VB expected_VBN to_TO result_VB in_IN an_DT impairment_NN of_IN cholinergic_JJ
        neurotransmission_NN and_CC /_NN or_CC in_IN a_DT generalized_JJ malfunction_NN of_IN
        cholinergic_JJ cells_NNS ._. Alzheimer_NNP 's_POS disease_NN (_( AD_NNP )_) is_VBZ
        characterized_VBN by_IN such_JJ a_DT malfunction_NN together_RB with_IN
        degeneration_NN of_IN basal_NN forebrain_NN cholinergic_JJ neurons_NNS ,_, and_CC it_PRP
        is_VBZ thought_VBN that_DT memory_NN loss_NN in_IN this_DT disease_NN is_VBZ partly_RB
        caused_VBN by_IN this_DT cholinergic_JJ lesion_NN [_NN 35_CD ]_NN ._. In_IN vitro_NN studies_NNS
        point_VBP to_TO two_CD novel_NN mechanisms_NNS that_WDT might_MD cause_VB
        dysregulation_NN of_IN PLD_NNP 2_CD activity_NN in_IN AD_NNP ._. The_DT first_JJ is_VBZ based_VBN on_IN
        observations_NNS that_IN PLD_NNP 2_CD is_VBZ inhibited_VBD by_IN α-synuclein_JJ [_NN 36_CD ]_NN ,_,
        a_DT protein_NN of_IN unknown_JJ function_NN that_IN accumulates_NNS in_IN the_DT
        amyloid_NN deposits_NNS in_IN AD_NNP brain_NN ._. Normally_RB α-synuclein_JJ is_VBZ
        present_JJ in_IN the_DT synaptic_JJ nerve_NN terminals_NNS (_( including_VBG those_DT of_IN
        cholinergic_JJ neurons_NNS [_NN 37_CD 38_CD ]_NN )_) but_CC in_IN AD_NNP its_PRP$ processing_NN is_VBZ
        altered_VBN ,_, causing_VBG it_PRP to_TO be_VB abnormally_RB deposited_VBN in_IN plaques_NNS
        composed_VBN primarily_RB of_IN aggregates_NNS of_IN β-amyloid_JJ peptide_NN [_NN 39_CD
        ]_NN ._. However_RB ,_, how_WRB this_DT abnormal_JJ turnover_NN of_IN α-synuclein_JJ
        contributes_VBZ to_TO the_DT pathophysiology_NN of_IN AD_NNP remains_VBZ to_TO be_VB
        determined_VBN ._. Recent_JJ in_IN vitro_NN observations_NNS that_IN α-synuclein_JJ
        is_VBZ phosphorylated_JJ by_IN G_NNP protein-coupled_JJ receptor_NN kinases_NNS ,_,
        and_CC that_IN this_DT phosphorylation_NN relieves_NNS its_PRP$ inhibitory_NN
        action_NN on_IN PLD_NNP 2_CD [_NN 40_CD ]_NN ,_, suggest_VBP a_DT novel_NN mechanism_NN by_IN which_WDT
        neurotransmitter_NN receptors_NNS (_( including_VBG muscarinic_JJ receptors_NNS )_)
        might_MD modulate_VBP PLD_NNP 2_CD activity_NN ._. Since_IN multiple_JJ receptor_NN
        classes_NNS are_VBP affected_VBN by_IN the_DT pathophysiological_JJ processes_NNS of_IN
        AD_NNP [_NN 41_CD ]_NN ,_, abnormal_JJ phosphorylation_NN of_IN α-synuclein_JJ may_MD
        contribute_VB to_TO both_DT altered_VBN α-synuclein_JJ turnover_NN and_CC
        abnormal_JJ regulation_NN of_IN PLD_NNP 2_CD activity_NN ._. The_DT second_RB set_NN of_IN
        observations_NNS indicate_VBP that_IN reactive_JJ oxygen_NN species_NNS (_( ROS_NNP )_)
        activate_VBP PLD_NNP 2_CD in_IN a_DT PKC-dependent_NNP manner_NN [_NN 9_CD ]_NN ._. There_EX is_VBZ
        much_JJ evidence_NN that_IN ROS_NNP generation_NN is_VBZ upregulated_JJ in_IN AD_NNP
        brain_NN [_NN 42_CD ]_NN ._. Thus_RB ,_, it_PRP is_VBZ possible_JJ that_IN PLD_NNP 2_CD may_MD be_VB
        activated_VBN in_IN this_DT disease_NN resulting_VBG ,_, perhaps_RB ,_, in_IN
        dysregulation_NN of_IN PC_NN metabolism_NN ._. Indeed_RB evidence_NN of_IN an_DT
        accelerated_VBN PC_NN turnover_NN has_VBZ been_VBN repeatedly_RB observed_VBN in_IN
        post-mortem_JJ samples_NNS of_IN AD_NNP brain_NN [_NN 43_CD 44_CD 45_CD 46_CD 47_CD ]_NN as_RB well_RB
        as_IN in_IN an_DT in_IN vitro_NN model_NN of_IN this_DT disease_NN characterized_VBN by_IN
        the_DT generation_NN of_IN ROS_NNP [_NN 48_CD ]_NN ._.
      
      
        Conclusions_NNP
        Most_JJS of_IN the_DT previous_JJ studies_NNS on_IN the_DT physiological_JJ
        functions_NNS PLDs_NNP have_VBP concentrated_VBN on_IN the_DT role_NN of_IN its_PRP$
        product_NN ,_, PA_NNP [_NN 7_CD ]_NN ._. Our_PRP$ data_NNS show_VBP that_IN PLD_NNP has_VBZ a_DT dual_JJ
        function_NN in_IN cholinergic_JJ cells_NNS ,_, as_IN the_DT second_JJ product_NN of_IN its_PRP$
        activity_NN ,_, choline_NN ,_, is_VBZ used_VBN as_IN a_DT metabolic_JJ precursor_NN of_IN ACh_NNP ,_,
        and_CC suggest_VBP that_IN this_DT pathway_NN may_MD be_VB regulated_VBN by_IN the_DT type_NN
        of_IN PLD_NNP isoform_NN expressed_VBD in_IN a_DT particular_JJ class_NN of_IN
        cholinergic_JJ neurons_NNS ._. In_IN our_PRP$ basal_NN forebrain-derived_JJ SN_NNP 56_CD
        cells_NNS ,_, this_DT isoform_NN is_VBZ PLD_NNP 2_CD ._. However_RB ,_, our_PRP$ observations_NNS that_IN
        PLD_NNP 1_CD overexpression_NN increases_NNS ACh_NNP production_NN form_NN
        endogenous_JJ sources_NNS suggest_VBP that_IN PLD_NNP 1_CD may_MD serve_VB the_DT same_JJ
        function_NN as_IN PLD_NNP 2_CD in_IN other_JJ cholinergic_JJ cells_NNS ._. Moreover_RB ,_, the_DT
        data_NNS showing_VBG that_IN this_DT pathway_NN is_VBZ stimulated_VBN by_IN PMA_NNP ,_,
        suggest_VBP that_IN it_PRP is_VBZ subject_JJ to_TO regulation_NN by_IN PKC-activating_NNP
        neurotransmitters_NNS ._. The_DT physiological_JJ ,_, and_CC possible_JJ
        pathophysiological_JJ significance_NN in_IN neurological_JJ diseases_NNS ,_,
        of_IN this_DT pathway_NN remains_VBZ to_TO be_VB determined_VBN ._. It_PRP will_MD also_RB be_VB
        important_JJ to_TO determine_VB how_WRB cholinergic_JJ cells_NNS regulate_VB the_DT
        metabolism_NN of_IN PA_NNP -_: a_DT compound_NN with_IN multiple_JJ signaling_VBG and_CC
        structural_JJ functions_NNS -_: when_WRB the_DT PLD_NNP pathway_NN is_VBZ stimulated_VBN
        to_TO meet_VB the_DT demand_NN for_IN choline_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Materials_NNS
          Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS medium_NN (_( DMEM_NNP )_) ,_, fetal_JJ
          bovine_JJ serum_NN (_( FBS_NNP )_) and_CC Lipofectamine_NNP Plus_NNP reagents_NNS were_VBD
          from_IN Gibco_NNP BRL_NNP Life_NNP Technologies_NNPS (_( Grand_NNP Island_NNP ,_, NY_NNP )_) ._.
          Phosphatidylpropanol_NNP (_( PP_NNP )_) was_VBD from_IN Avanti_NNP Polar_NNP Lipids_NNP
          (_( Alabaster_NNP ,_, AL_NNP )_) ._. Silica_NNP LK_NNP 6_CD Thin_NNP Layer_NNP Chromotography_NNP
          (_( TLC_NNP )_) plates_NNS were_VBD from_IN Whatman_NNP ._. [_NN 3_CD H_NNP ]_NN Myristic_NNP acid_NN and_CC
          [_NN α-_NN 32_CD P_NN ]_NN dCTP_NN were_VBD from_IN Dupont-_NNP NEN_NNP (_( Boston_NNP ,_, MA_NNP )_) ._. Molecular_NNP
          biology_NN reagents_NNS (_( except_IN as_IN noted_VBN )_) were_VBD from_IN Sigma_NNP (_( St_NNP ._.
          Louis_NNP ,_, MO_NNP )_) and_CC phorbol_NN 12_CD -_: myristate_NN 13_CD -_: acetate_NN was_VBD from_IN
          Calbiochem_NNP (_( La_NNP Jolla_NNP ,_, CA_NNP )_) ._. Polyclonal_NNP anti-human_JJ PLD_NNP 2_CD -_:
          and_CC anti-mouse_JJ PLD_NNP 1_CD antibodies_NNS were_VBD kindly_RB provided_VBN by_IN
          Dr_NNP ._. Yoshinori_NNP Nozawa_NNP (_( Gifu_NNP International_NNP Institute_NNP of_IN
          Biotechnology_NNP ,_, Japan_NNP )_) ._.
        
        
          Cell_NNP culture_NN
          Mouse_NNP septal_NN neuron_NN x_SYM neuroblastoma_NN hybrid_JJ SN_NNP 56_CD cells_NNS
          were_VBD maintained_VBN at_IN 37_CD °_NN C_NNP in_IN an_DT atmosphere_NN of_IN 95_CD %_NN air_NN ,_, 5_CD %_NN
          CO_NNP 
          2_CD in_IN DMEM_NNP supplemented_JJ with_IN 10_CD %_NN FBS_NNP ._.
          The_DT medium_NN was_VBD changed_VBN every_DT 2_CD -_: 3_CD days_NNS ._. Cells_NNP of_IN passage_NN
          10_CD to_TO 40_CD were_VBD used_VBN ._.
        
        
          Transient_NNP transfection_NN with_IN plasmids_NNS or_CC antisense_NN
          oligonucleotides_NNS
          The_DT pCGN_NN expression_NN vector_NN containing_VBG the_DT cDNAs_NNS of_IN
          mouse_NN PLD_NNP 2_CD (_( mPLD_NN 2_LS )_) or_CC human_JJ PLD_NNP 1_CD (_( hPLD_NN 1_LS )_) driven_VBN by_IN the_DT
          CMV_NNP promoter_NN were_VBD described_VBN previously_RB [_NN 5_CD 6_CD ]_NN ._. An_DT
          influenza-epitope_JJ (_( hemagglutinin-tag_JJ )_) is_VBZ inserted_VBN in_IN the_DT
          pCGN_NN vector_NN and_CC is_VBZ expressed_VBN at_IN the_DT N-_NNP terminus_JJ of_IN the_DT
          PLDs_NNP ._. The_DT SN_NNP 56_CD cells_NNS were_VBD grown_VBN to_TO about_IN 50_CD -_: 70_CD %_NN
          confluence_NN ,_, then_RB transiently_RB transfected_JJ with_IN these_DT
          plasmids_NNS using_VBG Lipofectamine_NNP Plus_NNP reagent_NN according_VBG to_TO
          the_DT manufacturer_NN 's_POS instructions_NNS ._. The_DT cells_NNS were_VBD assayed_JJ
          48_CD hours_NNS after_IN transfection_NN ._. Additional_JJ cultures_NNS were_VBD
          transfected_JJ with_IN a_DT β-galactosidase_JJ expression_NN plasmid_NN and_CC
          were_VBD stained_JJ on_IN the_DT day_NN of_IN the_DT experiment_NN (_( using_VBG staining_VBG
          kit_NN from_IN Invitrogen_NNP )_) to_TO estimate_VB transfection_NN efficiency_NN ._.
          The_DT overall_JJ transfection_NN efficiency_NN was_VBD about_IN 10_CD -_: 15_CD %_NN ._.
          A_DT mouse_NN PLD_NNP 2_CD antisense_NN oligonucleotide_NN was_VBD purchased_VBN
          from_IN Sequitur_NNP ,_, Inc_NNP ._. (_( Natick_NNP ,_, MA_NNP )_) ._. The_DT sequence_NN of_IN the_DT
          anti-m_JJ PLD_NNP 2_CD oligonucleotide_NN was_VBD
          5_CD '_POS -_: CAUGUGCAACUGGCUGGAGUUCAGA-_NNP 3_CD '_POS and_CC corresponded_VBD to_TO the_DT
          sequence_NN of_IN mouse_NN PLD_NNP 2_CD cDNA_NN (_( GeneBank_NNP accession_NN number_NN
          U_NNP 87557_CD )_) starting_VBG at_IN position_NN 180_CD ._. A_DT reversed_VBN control_NN
          oligonucleotide_NN was_VBD also_RB used_VBN and_CC its_PRP$ sequence_NN was_VBD
          5_CD '_POS -_: AGACUUGAGGUCGGUCAACGUGUAC-_NNP 3_CD '_'' ._. SN_NNP 56_CD cells_NNS were_VBD grown_VBN to_TO
          50_CD -_: 60_CD %_NN confluence_NN and_CC washed_VBN once_RB with_IN Opti-_NNP MEM_NNP (_( Gibco_NNP
          BRL_NNP )_) ._. The_DT oligonucleotides_NNS were_VBD diluted_VBN in_IN 100_CD μl_NN
          Opti-_NNP MEM_NNP to_TO various_JJ concentrations_NNS ,_, mixed_VBN with_IN 100_CD μl_NN of_IN
          Opti-_NNP MEM_NNP containing_VBG 6_CD μl_NN of_IN Lipofectamine_NNP and_CC incubated_JJ
          at_IN room_NN temperature_NN for_IN 20_CD minutes_NNS ._. The_DT mixture_NN was_VBD then_RB
          added_VBN to_TO 800_CD μl_NN of_IN serum-free_JJ DMEM_NNP and_CC the_DT cells_NNS were_VBD
          incubated_JJ in_IN this_DT medium_NN for_IN 4_CD hours_NNS at_IN 37_CD °_NN C_NNP and_CC then_RB
          cultured_JJ in_IN normal_JJ growth_NN medium_NN for_IN two_CD days_NNS before_IN
          assay_NN ._. A_DT fluorescent-dye_JJ labeled_VBN oligonucleotide_NN was_VBD also_RB
          purchased_VBN from_IN Sequitur_NNP Inc_NNP ._. and_CC used_VBN as_IN a_DT control_NN to_TO
          monitor_VB transfection_NN efficiency_NN ._. The_DT transfection_NN
          efficiency_NN was_VBD about_IN 30_CD -_: 40_CD %_NN ._.
        
        
          Northern_JJ blot_NN analysis_NN
          Northern_JJ blot_NN analysis_NN was_VBD carried_VBN out_IN essentially_RB as_IN
          described_VBN previously_RB [_NN 25_CD ]_NN using_VBG 20_CD μg_NN of_IN total_JJ RNA_NNP per_IN
          lane_NN and_CC 1_CD %_NN formaldehyde-agarose_JJ gel_NN containing_VBG ethidium_NN
          bromide_NN ._. The_DT RNA_NNP was_VBD size-fractionated_JJ by_IN electrophoresis_NNS
          and_CC transferred_VBN to_TO a_DT nylon_NN membrane_NN (_( HyBond_NNP ,_, Amersham_NNP )_) ._.
          The_DT PLD_NNP probes_NNS were_VBD :_: PLD_NNP 1_CD 661_CD bp_NN human_JJ PLD_NNP 1_CD cDNA_NN fragment_NN
          (_( GenBank_NNP accession_NN number_NN U_NNP 38545_CD ,_, pos_NNS ._. 951_CD -_: 1611_CD )_) isolated_VBN
          from_IN HeLa_NNP cell_NN cDNA_NN by_IN PCR_NNP ,_, and_CC PLD_NNP 2_CD (_( GenBank_NNP accession_NN
          number_NN U_NNP 87557_CD )_) excised_VBD from_IN the_DT pCGN-mPLD_JJ 2_CD plasmid_NN using_VBG
          endonuclease_NN Xbal_NNP and_CC Smal_NNP (_( 3000_CD bp_NN )_) ._. DNA_NN probes_NNS were_VBD
          labeled_VBN with_IN [_NN α-_NN 32_CD P_NN ]_NN dCTP_NN with_IN the_DT random_JJ primer_NN labeling_VBG
          kit_NN (_( Pharmacia_NNP Biotech_NNP Inc_NNP ._. ,_, NJ_NNP )_) ._. Prehybridization_NNP and_CC
          hybridization_NN steps_NNS were_VBD carried_VBN out_RB at_IN 65_CD °_NN C_NNP in_IN Rapid-_NNP Hyb_NNP
          solution_NN according_VBG to_TO manufacturer_NN 's_POS instructions_NNS ._. The_DT
          blots_NNS were_VBD washed_VBN and_CC exposed_VBN to_TO an_DT x-ray_JJ film_NN (_( Kodak_NNP
          BioMax_NNP MS-_NNP 2_CD film_NN ,_, Sigma_NNP )_) with_IN an_DT intensifying_VBG screen_NN at_IN
          -_: 80_CD °_NN C_NNP for_IN 4_CD days_NNS ._. Signal_NNP intensities_NNS were_VBD quantified_VBN with_IN
          ImageQuant_NNP software_NN (_( Molecular_NNP Dynamics_NNP )_) or_CC NIH_NNP Image_NN
          1_CD ._. 62_CD ._. Following_VBG Northern_NNP hybridization_NN with_IN these_DT probes_NNS ,_,
          the_DT blots_NNS were_VBD stripped_VBN and_CC re-probed_JJ with_IN a_DT mouse_NN G_NNP 3_CD PDH_NNP
          probe_NN for_IN normalization_NN purposes_NNS ._. For_IN these_DT experiments_NNS
          the_DT results_NNS are_VBP expressed_VBN as_IN units_NNS of_IN band_NN intensity_NN
          normalized_JJ with_IN G_NNP 3_CD PDH_NNP ._.
        
        
          Western_NNP blotting_VBG of_IN PLD_NNP isoforms_NNS
          Protein_NNP lysates_NNS from_IN whole_JJ cells_NNS and_CC tissues_NNS were_VBD
          prepared_VBN with_IN a_DT buffer_NN ,_, which_WDT contained_VBD 50_CD mM_NN Tris_NNP ,_, pH_NN
          7_CD ._. 5_CD ,_, 150_CD mM_NN NaCl_NNP ,_, 1_CD %_NN (_( v_NN /_NN v_NN )_) Nonidet_NNP P_NN 40_CD (_( NP_NNP 40_CD )_) ,_, 2_CD mM_NN
          4_CD -_: (_( 2_CD -_: aminoethyl_NN )_) benzenesulphonyl_NN fluoride_NN ,_, 1_CD μg_NN /_NN ml_NN
          leupeptin_NN ,_, 2_CD μg_NN /_NN ml_NN aprotinin_NN and_CC 2_CD μg_NN /_NN ml_NN pepstatin_NN ._.
          Lysates_NNP were_VBD mixed_JJ vigorously_RB ,_, incubated_JJ on_IN ice_NN for_IN 15_CD
          minutes_NNS and_CC cleared_VBN by_IN brief_JJ centrifugation_NN ._. The_DT
          extracts_NNS ,_, normalized_JJ for_IN total_JJ protein_NN content_NN ,_, were_VBD
          separated_VBN by_IN SDS_NNP /_NN PAGE_NNP and_CC transferred_VBN to_TO a_DT polyvinylidene_NN
          difluoride_NN membrane_NN (_( Immobilon-_NNP P_NN ,_, Millipore_NNP Corp_NNP ._. )_) ._. The_DT
          membrane_NN was_VBD blocked_VBN with_IN 5_CD %_NN non-fat_JJ milk_NN in_IN
          Tris-buffered_NNP saline_NN containing_VBG 0_CD ._. 15_CD %_NN Tween-_NNP 20_CD ._. The_DT
          polyclonal_NN anti-human_JJ PLD_NNP 2_CD antibody_NN and_CC anti-mouse_JJ PLD_NNP 1_CD
          antibody_NN were_VBD used_VBN to_TO detect_VB PLD_NNP 2_CD and_CC PLD_NNP 1_CD ,_, respectively_RB ._.
          The_DT membrane_NN was_VBD then_RB incubated_JJ with_IN anti-rabbit_JJ IgG_NNP
          peroxidase_NN conjugates_NNS ,_, and_CC proteins_NNS were_VBD visualized_JJ using_VBG
          the_DT chemiluminescence_NN method_NN (_( Luminol_NNP reagent_NN ,_, Santa_NNP Cruz_NNP
          Biotechnology_NNP )_) and_CC Kodak_NNP BioMax_NNP light_JJ film_NN (_( Fisher_NNP
          Scientific_NNP )_) ._. Some_DT blots_NNS were_VBD stripped_VBN by_IN incubating_VBG them_PRP
          at_IN 55_CD °_NN C_NNP for_IN 30_CD min_NN in_IN a_DT solution_NN containing_VBG Tris-_NNP HCl_NNP 62_CD ._. 5_LS
          mM_NN ,_, pH_NN 6_CD ._. 7_CD ,_, 2_CD %_NN SDS_NNP and_CC 100_CD mM_NN β-mercaptoethanol_JJ ,_, and_CC then_RB
          probed_JJ with_IN anti-mouse_JJ actin_NN antibody_NN (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_,
          MO_NNP )_) for_IN normalization_NN purposes_NNS ._. Signal_NNP intensities_NNS of_IN
          protein_NN bands_NNS were_VBD quantified_VBN with_IN NIH_NNP Image_NN 1_CD ._. 62_CD ._.
          Approximate_NNP molecular_JJ weights_NNS were_VBD estimated_VBN using_VBG
          prestained_JJ standards_NNS (_( NEN_NNP ,_, Boston_NNP ,_, MA_NNP )_) ._.
        
        
          In_IN vivo_NN assay_NN of_IN PLD_NNP activity_NN
          For_IN 
          in_IN vivo_NN assay_NN ,_, the_DT cells_NNS were_VBD grown_VBN
          to_TO subconfluence_NN and_CC prelabeled_JJ with_IN 2_CD μCi_NN /_NN ml_NN [_NN
          3_CD H_NNP ]_NN myristic_JJ acid_NN in_IN DMEM_NNP containing_VBG 10_CD %_NN FBS_NNP overnight_JJ ._.
          Labeled_NNP cells_NNS were_VBD incubated_JJ in_IN 1_CD ml_NN HEPES-buffered_NNP
          saline_NN solution_NN (_( HBS_NNP ,_, composition_NN in_IN mM_NN :_: NaCl_NNP ,_, 145_CD ;_: KCl_NNP ,_,
          5_CD ;_: MgSO_NNP 
          4_CD ,_, 1_CD ;_: CaCl_NNP 
          2_CD ,_, 1_CD ._. 8_CD ;_: glucose_NN ,_, 10_CD ;_: HEPES_NNP ,_, 10_CD ;_: pH_NN
          7_CD ._. 4_LS )_) at_IN 37_CD °_NN C_NNP for_IN 30_CD min_NN twice_RB to_TO wash_VB out_RP the_DT
          unincorporated_JJ label_NN ._. The_DT labeled_VBN cells_NNS were_VBD then_RB
          incubated_JJ in_IN the_DT presence_NN or_CC absence_NN of_IN 1_CD ._. 5_CD %_NN 1_CD -_: propanol_NN
          with_IN or_CC without_IN 100_CD nM_NN PMA_NNP at_IN 37_CD °_NN C_NNP for_IN 45_CD min_NN ._. The_DT
          reaction_NN was_VBD terminated_VBN by_IN adding_VBG ice-cold_JJ methanol_NN and_CC
          the_DT lipids_NNS were_VBD extracted_VBN in_IN a_DT solution_NN containing_VBG
          methanol_NN /_NN chloroform_NN /_NN water_NN (_( 1_CD :_: 1_CD :_: 1_CD v_NN /_NN v_NN )_) ._. The_DT lipids_NNS were_VBD
          dried_VBN and_CC separated_VBN by_IN TLC_NNP in_IN a_DT mobile_JJ phase_NN ,_, composed_VBN of_IN
          the_DT upper_JJ phase_NN of_IN a_DT mixture_NN of_IN ethyl_NN
          acetate_NN /_NN isooctane_NN /_NN acetic_JJ acid_NN /_NN water_NN (_( 130_CD :_: 20_CD :_: 30_CD :_: 100_CD v_NN /_NN v_NN )_) ,_,
          and_CC the_DT phospholipids_NNS were_VBD visualized_JJ with_IN
          l_NN ,_, 6_CD -_: diphenyl-l_JJ ,_, 3_CD ,_, 5_CD ,_, -_: hexatriene_NN in_IN hexane_NN ._. The_DT spots_NNS
          comigrating_VBG with_IN the_DT appropriate_JJ phospholipid_NN standards_NNS
          were_VBD scraped_JJ off_RP and_CC their_PRP$ radioactivity_NN was_VBD measured_VBN by_IN
          liquid_JJ scintillation_NN spectrophotometry_NN and_CC expressed_VBD as_IN a_DT
          percentage_NN of_IN the_DT radioactivity_NN present_JJ in_IN the_DT total_JJ
          lipids_NNS ._.
        
        
          Acetylcholine_NNP measurements_NNS
          The_DT cells_NNS were_VBD preincubated_JJ for_IN 20_CD minutes_NNS in_IN a_DT
          choline-free_JJ physiological_JJ salt_NN solution_NN (_( pH_NN 7_CD ._. 4_LS )_)
          consisting_VBG of_IN 135_CD mM_NN NaCl_NNP ,_, 5_CD mM_NN KCl_NNP ,_, 1_CD mM_NN CaCl_NNP 
          2_CD ,_, 0_CD ._. 75_CD mM_NN MgCl_NNP 
          2_CD ,_, 10_CD mM_NN glucose_NN and_CC 10_CD mM_NN HEPES_NNP ._. The_DT
          cells_NNS were_VBD then_RB incubated_JJ in_IN the_DT same_JJ buffer_NN supplemented_JJ
          with_IN 50_CD μM_NN neostigmine_NN (_( to_TO inhibit_VB acetylcholinesterase_NN )_)
          with_IN or_CC without_IN 100_CD nM_NN PMA_NNP for_IN 45_CD minutes_NNS ._. The_DT media_NNS were_VBD
          collected_VBN for_IN subsequent_JJ assays_NNS of_IN ACh_NNP and_CC choline_NN ._. The_DT
          cells_NNS were_VBD scraped_JJ into_IN 1_CD ml_NN of_IN methanol_NN and_CC this_DT mixture_NN
          transferred_VBN to_TO a_DT tube_NN containing_VBG 100_CD μl_NN 1_CD M_NNP formic_JJ acid_NN ,_,
          vortex_NN mixed_JJ and_CC centrifuged_JJ ._. The_DT pellet_NN was_VBD collected_VBN
          for_IN protein_NN assay_NN while_IN ACh_NNP was_VBD extracted_VBN by_IN mixing_VBG the_DT
          supernatant_NN fluid_JJ with_IN chloroform_NN and_CC water_NN (_( 1_CD :_: 2_CD :_: 1_CD v_NN /_NN v_NN )_) ._.
          The_DT samples_NNS were_VBD vortex_NN mixed_JJ and_CC centrifuged_JJ for_IN 5_CD
          minutes_NNS at_IN 3_CD ,_, 000_CD rpm_NN ._. The_DT aqueous_JJ phase_NN (_( containing_VBG ACh_NNP )_)
          was_VBD collected_VBN and_CC dried_VBN under_IN a_DT vacuum_NN ._. ACh_NNP content_NN was_VBD
          determined_VBN by_IN high_JJ performance_NN liquid_JJ chromatography_NN with_IN
          an_DT enzymatic_JJ reactor_NN containing_VBG acetylcholinesterase_NN and_CC
          choline_NN oxidase_NN and_CC an_DT electrochemical_JJ detector_NN using_VBG a_DT
          commercial_JJ kit_NN (_( Bioanalytical_NNP Systems_NNPS ,_, Inc_NNP ._. )_) based_VBN on_IN the_DT
          method_NN of_IN Potter_NNP et_CC al_NN ._. [_NN 49_CD ]_NN as_IN described_VBN previously_RB [_NN
          50_CD ]_NN ._. Protein_NNP concentration_NN was_VBD determined_VBN by_IN the_DT method_NN
          of_IN Smith_NNP et_CC al_NN ._. [_NN 51_CD ]_NN ._.
        
        
          Statistical_NNP Analysis_NNP
          Data_NNP presented_VBD in_IN the_DT figures_NNS were_VBD derived_VBN from_IN 3_CD -_: 9_CD
          independent_JJ experiments_NNS and_CC were_VBD analyzed_VBN using_VBG Systat_NNP
          5_CD ._. 2_CD ._. 1_LS (_( SPSS_NNP Inc_NNP ._. ,_, Chicago_NNP ,_, Ill_NNP )_) by_IN t-test_JJ or_CC analysis_NN of_IN
          variance_NN as_IN appropriate_JJ ._. Tukey_NNP or_CC Fisher_NNP LSD_NNP were_VBD used_VBN
          for_IN post_NN hoc_FW tests_NNS ._. Differences_NNS were_VBD considered_VBN to_TO be_VB
          significant_JJ at_IN p_NN <_NN 0_CD ._. 05_CD ._.
        
      
      
        Abbreviations_NNP
        1_LS ACh_NNP ,_, acetylcholine_NN ;_: ARF_NNP ,_, ADP-ribosylation_NNP factor_NN ;_: DAG_NNP ,_,
        diacylglycerol_NN ;_: G_NNP 3_CD PDH_NNP ,_, glyceraldehyde_NN 3_CD -_: phosphate_NN
        dehydrogenase_NN ;_: MAChR_NNP ,_, muscarinic_JJ acetylcholine_NN receptor_NN ;_:
        PA_NNP ,_, phosphatidic_JJ acid_NN ;_: PC_NN ,_, phosphatidylcholine_NN ;_: PIP_NNP 
        2_CD ,_, phosphatidylinositol_NN 4_CD ,_,
        5_CD -_: bisphosphate_NN ;_: PKC_NNP ,_, protein_NN kinase_NN C_NNP ;_: PLD_NNP ,_, phospholipase_NN
        D_NNP ;_: PMA_NNP ,_, phorbol_NN 12_CD -_: myristate_NN 13_CD -_: acetate_NN ;_: PP_NNP ,_,
        phosphatidylpropanol_NN ;_: ROS_NNP ,_, reactive_JJ oxygen_NN species_NNS ;_: TLC_NNP ,_,
        thin_JJ layer_NN chromatography_NN ._.
      
    
  
